Global nanotechnology company pSivida Limited, is pleased to announce that its UK operating subsidiary pSiMedica Limited has been granted a new Australian patent for BioSiliconTM.Australian
At the international AIDS conference in Bangkok, AIDS Healthcare Foundation hosted a peaceful protest against British multinational pharmaceutical giant
Matsushita (Panasonic) has announced its environment-related subsidiary, Matsushita Ecology Systems Co., Ltd., has developed a revolutionary SARS air filter. The new filter neutralizes or ina
Cancer Research Technology announced today that it has entered into a license agreement granting Genentech, Inc. exclusive worldwide rights to its patent portfolio covering an oncology targ
AstraZeneca has confirmed that it has filed a lawsuit in the U.S. District Court for the District of Delaware against the generic company Andrx for patent infringement.The lawsuit is th
PRB Pharmaceuticals and Lee's Pharmaceuticals have announced the discovery that PRB'S patent pending botanical extract, V38-AMF-1, comp
Last tuesday marked the conclusion of a patent trial involving discontinued trocar products by United States Surgical, a market leader and innovator of minimally invasive surgical instruments.Following an earlier February 2002 infringement ruli
Zyomyx a privately held biotechnology company, has announced that the United States Patent and Trademark Office issued five new patents to the Company. With these additions, Zyomyx has further strength
Cyntellect a privately-held biotechnology company, has announced the issuance of U.S. Patent No. 6,753,161 covering the Company's LaserFect(TM) technology.LaserFect represents the first tec
The Institute of Cancer Research and Cancer Research Technology Limited, the technology transfer company of the charity
The first gene, involved in copying DNA, was linked specifically to pancreatic and ovarian cancers, which are notoriously hard to diagnose at an early stage. It could help in the early diagnosis of patients at high risk for these cancers, as well as serve as a possible drug target for treatment of these poorly treatable diseases.
The second gene codes for a scaffolding protein involved in building protein networks inside the cell. It was linked to all six common cancers (lung, colon, breast, prostate, ovarian, and pancreatic), and may lead to new broad-spectrum chemotherapeutic agents.
Said Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, "We still have to validate our initial results. The best news is that our conveyor belt for finding new disease genes is up and running. We're now testing one or two genes a week in our own lab, and will soon be testing tens of thousands of genes at a time through our collaboration with Genome Quebec."
http://www.genomedics.com/